Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)
Clinical trial NCT01050543 · COMPLETED
Trial details
- NCT number
- NCT01050543
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-02-01
- Primary completion
- 2010-08-20
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.